Last A$5.88 AUD
Change Today +0.08 / 1.38%
Volume 86.7K
As of 12:10 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

fisher & paykel healthcare c (FPH) Snapshot

Open
A$5.92
Previous Close
A$5.80
Day High
A$5.93
Day Low
A$5.85
52 Week High
12/19/14 - A$6.05
52 Week Low
02/11/14 - A$3.56
Market Cap
3.3B
Average Volume 10 Days
259.3K
EPS TTM
--
Shares Outstanding
557.9M
EX-Date
12/3/14
P/E TM
--
Dividend
A$0.18
Dividend Yield
2.80%
Current Stock Chart for FISHER & PAYKEL HEALTHCARE C (FPH)

Related News

No related news articles were found.

fisher & paykel healthcare c (FPH) Related Businessweek News

No Related Businessweek News Found

fisher & paykel healthcare c (FPH) Details

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, and markets medical device products and systems for use in respiratory and acute care, and the treatment of obstructive sleep apnea. The company operates through four segments: New Zealand, North America, Europe, and Asia-Pacific. It provides respiratory humidifiers, single-use and reusable chambers, and breathing circuits and accessories that are designed to humidify and deliver the gases that a patient receives during mechanical ventilation, non-invasive ventilation, oxygen therapy, humidity therapy and laparoscopic surgery. The company offers neonatal care products include infant resuscitators and continuous positive airway pressure (CPAP) systems designed to enhance infant respiratory function. It also provides CPAP therapy products, including integrated flow generator-humidifiers, tubings, and masks to deliver humidified airflow to patients during CPAP therapy. In addition, the company offers HumiGard surgical humidification system that prevents unnecessary cellular damage by protecting tissue against the harmful effects of cold and dry carbon dioxide2, as well as protects against damage caused by cold, dry surgical gas during laparoscopic surgery. Fisher & Paykel Healthcare Corporation Limited sells its products through its distribution subsidiaries, third party distributors, and original equipment manufacturers to hospitals, homecare providers, and other manufacturers of medical devices. The company was founded in 1934 and is headquartered in Auckland, New Zealand.

Founded in 1934

fisher & paykel healthcare c (FPH) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2014.

fisher & paykel healthcare c (FPH) Key Developments

Fisher & Paykel Healthcare Corporation Limited Reports Unaudited Consolidated Cash Flow Results for the Six Months Ended September 30, 2014

Fisher & Paykel Healthcare Corporation Limited reported unaudited consolidated cash flow results for the six months ended September 30, 2014. For the period, the company reported net cash flows from operations of NZD 58,619,000 against NZD 33,408,000 for the same period a year ago. Purchases of property, plant and equipment was NZD 20,532,000 against NZD 17,136,000 for the same period a year ago. Purchases of intangible assets was NZD 4,955,000 against NZD 1,328,000 for the same period a year ago.

Fisher & Paykel Healthcare Corporation Limited Approves Interim Dividend and Supplementary Dividend, Payable on 19 December 2014

The directors of Fisher & Paykel Healthcare Corporation Limited have approved an increased interim dividend of 5.8 NZ cents per ordinary share carrying a full imputation credit of 2.2556 NZ cents per share. Eligible non-resident shareholders will receive a supplementary dividend of 1.0235 NZ cents per share. The interim dividend will be paid on 19 December 2014, with a record date of 5 December 2014 and an ex-dividend date of 3 December 2014 for the NZSX and ASX.

Fisher & Paykel Healthcare Corporation Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Fisher & Paykel Healthcare Corporation Limited reported unaudited consolidated earnings results for the six months ended September 30, 2014. For the period, the company reported profit after tax was NZD 48,917,000 or 8.6 NZD cents per diluted share on operating revenue was NZD 317,442,000 against profit after tax of NZD 44,492,000 or 7.9 NZD cents per diluted share on operating revenue was NZD 303,917,000 a year ago. The increase in the half year net profit after tax reflects revenue growth, further gross margin expansion and other operational efficiencies, partially offset by a reduction in foreign exchange hedging gains. Profit before tax was NZD 66,909,000 compared to NZD 62,593,000 a year ago. Net cash flows from operations were NZD 58,619,000 compared to NZD 33,408,000 a year ago. The increase was mainly related to improved receipts from customers reflecting higher sales and improvements in gross margin. Net purchase of property, plant and equipment was NZD 20,529,000 compared to NZD 17,117,000 a year ago. Purchases of intangible assets were NZD 4,955,000 compared to NZD 1,328,000 a year ago. The increase in intangible expenditure related to costs for an ERP project the company is undertaking to position itself for future growth. EBITDA for the period was NZD 88.3 million compared to NZD 82.3 million last half year, an increase of 7%. Operating profit before financing costs was NZD 72,623,000 compared with NZD 66,939,000 a year ago. Capital expenditure for the period was NZD 25.5 million compared with NZD 18.4 million in the prior half year. For the fiscal year 2015, the company expects full year operating revenue to be approximately NZD 660 million and net profit after tax to be approximately NZD 105 million to NZD 110 million. Capex for the full 2015 year will be higher than the 2014 year as the level of expenditure for development projects reaching significant milestones will be greater. The company expects 2015 Capex to be approximately NZD 50 million. The effective tax rate for the group should be around 29% for the 2015 financial year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FPH:AU A$5.88 AUD +0.08

FPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apex Medical Corp/Taiwan 58.20 TWD -0.60
ResMed Inc $62.47 USD -0.56
View Industry Companies
 

Industry Analysis

FPH

Industry Average

Valuation FPH Industry Range
Price/Earnings 31.8x
Price/Sales 5.0x
Price/Book 7.7x
Price/Cash Flow 31.8x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FISHER & PAYKEL HEALTHCARE C, please visit www.fphcare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.